Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44 Page 45 Page 46 Page 47 Page 48 Page 49 Page 50 Page 51 Page 52 Page 53 Page 54 Page 55 Page 56 Page 57 Page 58 Page 59 Page 60 Page 61 Page 62 Page 63 Page 64 Page 65 Page 66 Page 67 Page 68Chest pain may occur either as part of the immediate postinjection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your doctor if you experience chest pain that lasts for a long time or feels very intense. A permanent indentation under the skin (lipoatrophy or, rarely, necrosis) at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes. The most common side effects in studies of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of COPAXONE® . For a complete list, ask your doctor or pharmacist. Tell your doctor about any side effects you have while taking COPAXONE® . You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/ medwatch or call 1-800-FDA-1088. Please see brief summary of full Prescribing Information on the following page. Take control of managing your relapsing MS with 3-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg: t The #1 prescribed therapy for relapsing MS in the US1 * t Proven clinically effective2 t
Demonstrated safety and tolerability profile2 t
Injections must be at least 48 hours apart t
The financial support, training and nurse support, and educational resources of Teva’s Shared Solutions® *Based on total number of prescriptions for relapsing forms of MS (IMS National Rx Audit, June 2016). All Rights Reserved by IMS. Arrange your treatment around your life—not your life around your treatment